Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi Pasteur to launch dengue vaccine paediatric study

Sanofi Pasteur to launch dengue vaccine paediatric study

18th February 2009

Sanofi Pasteur has announced its investigational tetravalent dengue vaccine will be the first of its kind to enter a paediatric clinical study.

The firm began developing a vaccine against dengue – a mosquito-borne disease that is a threat to nearly half of the world’s population – during the 1990s. Clinical studies began a decade later with the most advanced tetravalent candidate vaccine.

Now, the company will assess the efficacy of the treatment in protecting youngsters against the illness. Out of the estimated 230 million sufferers, two million ? mostly children – develop a severe form of the disease known as dengue hemorrhagic fever.

The trial will follow guidelines from the Initiative for Vaccine Research (IVR), set out by the World Health Organisation (Who).

Dr Joachim Hombach, co-ordination implementation research for IVR at Who, commented: “Who is committed to the availability of a dengue vaccine that will ultimately benefit children in endemic countries.”

Sanofir Pasteur also reported this week it will be sponsoring studies to develop a protective treatment against Clostridium difficile, which is one of the most common causes of hospital-acquired infection in Europe.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.